These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 22814417)

  • 1. Deal watch: Roche deal targets glutamate in neurodevelopmental disorders.
    Harrison C
    Nat Rev Drug Discov; 2012 Aug; 11(8):590. PubMed ID: 22814417
    [No Abstract]   [Full Text] [Related]  

  • 2. Biomedical research. A fix for fragile X syndrome?
    Miller G
    Science; 2006 Apr; 312(5773):521. PubMed ID: 16645065
    [No Abstract]   [Full Text] [Related]  

  • 3. Trialing targeted therapies for autism.
    Nat Med; 2012 Dec; 18(12):1746-7. PubMed ID: 23223062
    [No Abstract]   [Full Text] [Related]  

  • 4. Open-label riluzole in fragile X syndrome.
    Erickson CA; Weng N; Weiler IJ; Greenough WT; Stigler KA; Wink LK; McDougle CJ
    Brain Res; 2011 Mar; 1380():264-70. PubMed ID: 21059347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mGluR antagonists and GABA agonists as novel pharmacological agents for the treatment of autism spectrum disorders.
    Oberman LM
    Expert Opin Investig Drugs; 2012 Dec; 21(12):1819-25. PubMed ID: 23013434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fragile X Syndrome and Alzheimer's Disease: Another story about APP and beta-amyloid.
    Malter JS; Ray BC; Westmark PR; Westmark CJ
    Curr Alzheimer Res; 2010 May; 7(3):200-6. PubMed ID: 20088809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabotropic glutamate receptors: synaptic modulators and therapeutic targets for neurologic disease.
    Benarroch EE
    Neurology; 2008 Mar; 70(12):964-8. PubMed ID: 18347319
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond.
    Gross C; Berry-Kravis EM; Bassell GJ
    Neuropsychopharmacology; 2012 Jan; 37(1):178-95. PubMed ID: 21796106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tweaking the social network.
    Gomez-Mancilla B
    Sci Transl Med; 2012 Apr; 4(131):131fs9. PubMed ID: 22539770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [L-glutamate and the formation of the long-term memory in the honey bee Apis mellifera].
    Lopatina NG; Ryzhova IV; Zachepilo TG; Smirnova VB; Chesnokova EG
    Zh Evol Biokhim Fiziol; 2004; 40(6):539-45. PubMed ID: 15929416
    [No Abstract]   [Full Text] [Related]  

  • 11. Selective blockade of type-1 metabotropic glutamate receptors induces neuroprotection by enhancing gabaergic transmission.
    Battaglia G; Bruno V; Pisani A; Centonze D; Catania MV; Calabresi P; Nicoletti F
    Mol Cell Neurosci; 2001 Jun; 17(6):1071-83. PubMed ID: 11414795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neurochemical basis for the treatment of autism spectrum disorders and Fragile X Syndrome.
    Hampson DR; Adusei DC; Pacey LK
    Biochem Pharmacol; 2011 May; 81(9):1078-86. PubMed ID: 21333634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Metabotropic glutamate receptors as targets for new drug development].
    Arkhipov VI; Kapralova MV
    Eksp Klin Farmakol; 2011; 74(10):46-52. PubMed ID: 22238988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fragile X syndrome therapeutics S(C)TEP through the developmental window.
    Bhattacharya A; Klann E
    Neuron; 2012 Apr; 74(1):1-3. PubMed ID: 22500622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NMDA receptor pathways as drug targets.
    Kemp JA; McKernan RM
    Nat Neurosci; 2002 Nov; 5 Suppl():1039-42. PubMed ID: 12403981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism-based approaches to treating fragile X.
    Dölen G; Carpenter RL; Ocain TD; Bear MF
    Pharmacol Ther; 2010 Jul; 127(1):78-93. PubMed ID: 20303363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding.
    Litschig S; Gasparini F; Rueegg D; Stoehr N; Flor PJ; Vranesic I; Prézeau L; Pin JP; Thomsen C; Kuhn R
    Mol Pharmacol; 1999 Mar; 55(3):453-61. PubMed ID: 10051528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antagonists at metabotropic glutamate receptor subtype 5: structure activity relationships and therapeutic potential for addiction.
    Carroll FI
    Ann N Y Acad Sci; 2008 Oct; 1141():221-32. PubMed ID: 18991960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathways to drug development for autism spectrum disorders.
    Hampson DR; Gholizadeh S; Pacey LK
    Clin Pharmacol Ther; 2012 Feb; 91(2):189-200. PubMed ID: 22205199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome.
    McBride SM; Choi CH; Wang Y; Liebelt D; Braunstein E; Ferreiro D; Sehgal A; Siwicki KK; Dockendorff TC; Nguyen HT; McDonald TV; Jongens TA
    Neuron; 2005 Mar; 45(5):753-64. PubMed ID: 15748850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.